77 TRENDS IN PREVALENCE AND ANTITHROMBOTIC PRESCRIPTIONS IN AF 17. Krijthe BP, Kunst A, Benjamin EJ, Lip GYH, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746–51. 18. Buddeke J, Valstar GB, Van Dis I, Visseren FLJ, Rutten FH, Den Ruijter HM, et al. Mortality after hospital admission for heart failure: Improvement over time, equally strong in women as in men. BMC Public Health. 2020;20(1):1–10. 19. Koopman C, Bots ML, van Dis I, Vaartjes I. Shifts in the age distribution and from acute to chronic coronary heart disease hospitalizations. Eur J Prev Cardiol. 2016;23(2):170–7. 20. Huisman M V., Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: The GLORIA-AF Registry, Phase II. Am J Med. 2015;128(12):1306-1313.e1. 21. Bassand JP, Apenteng PN, Atar D, Camm AJ, Cools F, Corbalan R, et al. GARFIELD-AF: A worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol. 2021;17(1):19–38. 22. Steinberg BA, Greiner MA, Hammill BG, Curtis LH, Benjamin EJ, Heckbert SR, et al. Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. Cardiovasc Ther. 2015;33(4):177–83. 23. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med. 2010;123(7):638-45.e4. 24. Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132–40. 25. van Doorn S, Brakenhoff TB, Moons KGM, Rutten FH, Hoes AW, Groenwold RHH, et al. The effects of misclassification in routine healthcare databases on the accuracy of prognostic prediction models: A case study of the CHA2DS2-VASc score in atrial fibrillation. Diagn Prog Res. 2017;1:18. 26. van den Dries CJ, van Doorn S, Rutten FH, Oudega R, van de Leur SJCM, Elvan A, et al. Integrated management of atrial fibrillation in primary care: Results of the ALL-IN cluster randomized trial. Eur Heart J. 2020;41(30):2836–44. 27. NHG-werkgroep Atriumfibrilleren. NHG-Standaard Atriumfibrilleren. Huisarts Wet. 2017;60:460. 28. Kim DH, Pawar A, Gagne JJ, Bessette LG, Lee H, Glynn RJ, et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation. Ann Intern Med. 2021;174(9):1214–23. 29. Joosten LPT, Van Doorn S, Hoes AW, Nierman MC, Wiersma NM, Koek HL, et al. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: Rationale and design of the FRAIL-AF randomised controlled trial. BMJ Open. 2019;9(12):e032488. 5
RkJQdWJsaXNoZXIy MTk4NDMw